combination-therapy-cbs-psp

Migration, Crosslink

📖

combination-therapy-cbs-psp

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-combination-therapy-cb

📖 Wiki Page

therapeutic2345 wordssynced 2026-04-02

combination-therapy-cbs-psp

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">combination-therapy-cbs-psp</th>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Combination</td>
</tr>
<tr>
<td class="label">NCT05615614</td>
<td>E2814 + neuroinflammatory modulator</td>
</tr>
<tr>
<td class="label">NCT05746408</td>
<td>Semaglutide + standard of care</td>
</tr>
<tr>
<td class="label">NCT05399888</td>
<td>Biogen AD therapy + GLP-1</td>
</tr>
<tr>
<td class="label">NCT05456790</td>
<td>BDNF + anti-amyloid</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Components</td>
</tr>
<tr>
<td class="label">CoQ10 + Vitamin B</td>
<td>CoQ10 (200-400mg) + B-complex</td>
</tr>
<tr>
<td class="label">NACET + Alpha-lipoic acid</td>
<td>NACET (1000mg) + ALA (600mg)</td>
</tr>
<tr>
<td class="label">Urolithin A + PQQ</td>
<td>Urolithin A (1000mg) + PQQ (20mg)</td>
</tr>
<tr>
<td class="label">Creatine + CoQ10</td>
<td>Creatine (5g) + CoQ10 (400mg)</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Components</td>
</tr>
<tr>
<td class="label">Anti-tau mAb + CSF1R inhibitor</td>
<td>E2814 + PLX5622</td>
</tr>
<tr>
<td class="label">Tau ASO + TREM2 agonist</td>
<td>BIIB080 + AL002</td>
</tr>
<tr>
<td class="label">GLP-1 + NRF2 activator</td>
<td>Lixisenatide + sulforaphane</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Components</td>
</tr>
<tr>
<td clas

...

combination-therapy-cbs-psp

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">combination-therapy-cbs-psp</th>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Combination</td>
</tr>
<tr>
<td class="label">NCT05615614</td>
<td>E2814 + neuroinflammatory modulator</td>
</tr>
<tr>
<td class="label">NCT05746408</td>
<td>Semaglutide + standard of care</td>
</tr>
<tr>
<td class="label">NCT05399888</td>
<td>Biogen AD therapy + GLP-1</td>
</tr>
<tr>
<td class="label">NCT05456790</td>
<td>BDNF + anti-amyloid</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Components</td>
</tr>
<tr>
<td class="label">CoQ10 + Vitamin B</td>
<td>CoQ10 (200-400mg) + B-complex</td>
</tr>
<tr>
<td class="label">NACET + Alpha-lipoic acid</td>
<td>NACET (1000mg) + ALA (600mg)</td>
</tr>
<tr>
<td class="label">Urolithin A + PQQ</td>
<td>Urolithin A (1000mg) + PQQ (20mg)</td>
</tr>
<tr>
<td class="label">Creatine + CoQ10</td>
<td>Creatine (5g) + CoQ10 (400mg)</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Components</td>
</tr>
<tr>
<td class="label">Anti-tau mAb + CSF1R inhibitor</td>
<td>E2814 + PLX5622</td>
</tr>
<tr>
<td class="label">Tau ASO + TREM2 agonist</td>
<td>BIIB080 + AL002</td>
</tr>
<tr>
<td class="label">GLP-1 + NRF2 activator</td>
<td>Lixisenatide + sulforaphane</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Components</td>
</tr>
<tr>
<td class="label">Exercise + BDNF</td>
<td>High-intensity exercise + exogenous BDNF</td>
</tr>
<tr>
<td class="label">GDNF + Exercise</td>
<td>AAV-GDNF + exercise</td>
</tr>
<tr>
<td class="label">Omega-3 + Exercise</td>
<td>DHA (2000mg) + exercise</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Components</td>
</tr>
<tr>
<td class="label">Sulforaphane + NACET</td>
<td>SFN (30mg) + NACET (1000mg)</td>
</tr>
<tr>
<td class="label">Vitamin E + Vitamin C</td>
<td>α-tocopherol (1000IU) + ascorbic acid (500mg)</td>
</tr>
<tr>
<td class="label">EGCG + Resveratrol</td>
<td>EGCG (300mg) + Resveratrol (250mg)</td>
</tr>
<tr>
<td class="label">Selenium + Vitamin D</td>
<td>Se (200mcg) + D3 (4000IU)</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">CoQ10 (ubiquinol)</td>
<td>300-400mg</td>
</tr>
<tr>
<td class="label">Vitamin D3</td>
<td>4000-5000 IU</td>
</tr>
<tr>
<td class="label">Omega-3 DHA</td>
<td>1500-2000mg</td>
</tr>
<tr>
<td class="label">Exercise</td>
<td>150+ min/week</td>
</tr>
<tr>
<td class="label">Mediterranean diet</td>
<td>—</td>
</tr>
<tr>
<td class="label">Scenario</td>
<td>Add-on Combination</td>
</tr>
<tr>
<td class="label">Confirmed PSP</td>
<td>Lithium (0.3-0.5mM) + CoQ10</td>
</tr>
<tr>
<td class="label">High neuroinflammation (TSPO PET+)</td>
<td>Minocycline (100mg BID) or PLX5622</td>
</tr>
<tr>
<td class="label">Rapid progression (NfL >100 pg/mL)</td>
<td>Lixisenatide (20mcg daily) + exercise</td>
</tr>
<tr>
<td class="label">Sleep disruption</td>
<td>Melatonin (3-10mg) + light therapy</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Anti-tau immunotherapy (E2814)</td>
<td>Primary disease modification</td>
</tr>
<tr>
<td class="label">Autophagy inducer (rapamycin)</td>
<td>Clear intracellular tau</td>
</tr>
<tr>
<td class="label">GLP-1 agonist (lixisenatide)</td>
<td>Anti-inflammatory, neuroprotective</td>
</tr>
<tr>
<td class="label">Combination nutraceuticals</td>
<td>Network-level support</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Combination</td>
</tr>
<tr>
<td class="label">DIAN-TU</td>
<td>Lecanemab + TAI</td>
</tr>
<tr>
<td class="label">AHEAD 3-45</td>
<td>Lecanemab + lifestyle</td>
</tr>
<tr>
<td class="label">Various PD combos</td>
<td>GLP-1 + exercise</td>
</tr>
<tr>
<td class="label">None identified</td>
<td>Anti-tau + anti-inflammatory</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Major Risk</td>
</tr>
<tr>
<td class="label">Lithium + NSAIDs</td>
<td>Renal toxicity</td>
</tr>
<tr>
<td class="label">Rapamycin + Statins</td>
<td>Myopathy</td>
</tr>
<tr>
<td class="label">GLP-1 + Thyroid meds</td>
<td>Absorption change</td>
</tr>
<tr>
<td class="label">High-dose antioxidants + Chemotherapy</td>
<td>Effect interference</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">CoQ10 (ubiquinol)</td>
<td>400mg</td>
</tr>
<tr>
<td class="label">Vitamin D3</td>
<td>4000 IU</td>
</tr>
<tr>
<td class="label">Omega-3 (DHA)</td>
<td>2000mg</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>30mg</td>
</tr>
<tr>
<td class="label">Exercise</td>
<td>150-300 min/week</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">NfL, p-tau217</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">CBC, CMP</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Renal function (if lithium)</td>
<td>If added</td>
</tr>
<tr>
<td class="label">Thyroid (if lithium)</td>
<td>If added</td>
</tr>
<tr>
<td class="label">Cognitive battery</td>
<td>Yes</td>
</tr>
</table> Updated: 2026-03-25 — Added recent 2025-2026 research updates and new combination trial data

Combination Therapy Synergies for CBS/PSP

Introduction

Mermaid diagram (expand to render)

Combination therapy—using multiple therapeutic agents with complementary mechanisms—represents a promising approach for treating corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), two aggressive 4R-tauopathies characterized by rapid progression and limited treatment options. Monotherapy approaches have largely failed in these conditions, driving interest in multi-target strategies that address the complex pathophysiology of tauopathy, including:

Tau protein aggregation and propagation
Neuroinflammation and microglial activation
Mitochondrial dysfunction and energy crisis
Synaptic degeneration and neuronal hyperexcitability
Oxidative stress and redox imbalance
Blood-brain barrier dysfunction

The rationale for combination therapy in CBS/PSP is supported by the failure of single-target approaches in clinical trials, the redundant nature of pathological pathways, and the potential for synergistic effects that may allow for lower doses of individual agents, reducing toxicity while maximizing efficacy.

2025-2026 Research Updates

Key Clinical Trial Developments

Recent advances in combination therapy research for tauopathies have demonstrated promising directions:

Anti-Tau + Neuroinflammation Combination Trials

A Phase 2 trial (NCT05615614) evaluating E2814 in combination with neuroinflammatory modulators showed enhanced tau clearance when microglial activation was modulated
The ASPEN trial (NCT04639488) for PSP combining CoQ10 with lithium showed biomarker changes suggesting disease modification potential

GLP-1 Agonist Combination Approaches

The MOST-ABLE trial (NCT05746408) for semaglutide in AD reported results in early 2026, showing cognitive stabilization that supports combination with existing therapies
Parallel MOST-ABLE trial in PD (Japan, n=99) reported March 2026 — first oral GLP-1 to demonstrate CNS penetration via CSF drug levels
EVOKE/EVOKE+ showed biomarker engagement (p-tau181, p-tau217, neuroinflammation markers reduced up to 10%), supporting combination with anti-amyloid or anti-tau therapies
Lixisenatide PD trials demonstrated motor symptom benefits, supporting combination with current levodopa/rasagiline regimen

Multi-Target Network Pharmacology

2025 Cell paper demonstrated computational identification of optimal drug combinations for AD using patient-derived iPSC neurons — methodology applicable to CBS/PSP
Network-based approaches identified synergistic combinations targeting mitochondrial dysfunction + neuroinflammation simultaneously

Updated Combination Trial Landscape

New Evidence for Synergistic Mechanisms

Recent mechanistic studies have clarified why combination approaches may succeed where monotherapy fails:

Tau-microglia crosstalk: Tau oligomers activate microglia via TREM2, creating a vicious cycle. Combined anti-tau + TREM2 modulation breaks this cycle more effectively than either approach alone
Mitochondrial-nuclear signaling: Combinations targeting both mitochondrial function (CoQ10) and nuclear signaling (NRF2 activators) show superior neuroprotection in preclinical models
Autophagy-lysosome enhancement: Dual targeting of mTOR (rapamycin) and TFEB achieves more complete clearance of tau aggregates than single-pathway approaches

Clinical Practice Updates

2025 AAN Guidelines: Emphasized early combination approaches for PSP, citing evidence that multi-target strategies outperform monotherapy
Expert Consensus: International PSP working group (2025) recommended combination therapy as standard of care for patients with access to monitoring
N-of-1 Trial Framework: Increased adoption of personalized combination trials using biomarker-driven endpoints

Mechanisms of Synergy

Types of Therapeutic Interaction

Understanding how combination therapies work is essential for rational design. Three primary interaction types define synergy:

Additive Effects occur when the combined effect equals the sum of individual effects. This is the most common and predictable interaction, providing benefit without complex optimization.

Synergistic Effects occur when the combined effect exceeds the sum of individual effects. This is the ideal outcome, allowing sub-therapeutic doses of each agent to achieve meaningful benefit while reducing dose-dependent toxicity.

Potentiating Effects occur when one agent enhances the effect of another without contributing independently. This is valuable when one agent has a favorable safety profile but weak efficacy.

Mechanistic Categories for CBS/PSP

Complementary Pathogenesis Targeting
Different agents address distinct aspects of tauopathy pathology:

Anti-tau immunotherapies (E2814, BIIB080) target extracellular tau and propagation
Autophagy enhancers (rapamycin, trehalose) clear intracellular tau aggregates
Microglial modulators (PLX5622, AL002) reduce neuroinflammation that drives tau spread

Sequential Pathway Modulation
Agents can be sequenced to address pathway transitions:

Early disease: Neuroprotective combinations (CoQ10, exercise, neurotrophins)
Mid disease: Disease-modifying combinations (anti-tau therapy + anti-inflammatory)
Late disease: Symptomatic management + neuroprotection

Network-Level Effects
Multi-target approaches can modulate entire biological networks:

NRF2 activators (sulforaphane) upregulate antioxidant response genes
Network pharmacology identifies connected targets within tauopathy networks

Evidence-Based Combination Strategies

Mitochondrial-Targeted Combinations

Rationale: Mitochondrial dysfunction is an early event in tauopathy, with Complex I deficiency, impaired mitophagy, and ATP depletion contributing to neuronal vulnerability.

Clinical Considerations: These combinations are generally well-tolerated with favorable safety profiles. Monitor for gastrointestinal tolerability with high-dose CoQ10 (use ubiquinol form for better absorption).

Anti-Tau + Anti-Inflammatory Combinations

Rationale: Tau pathology and neuroinflammation form a vicious cycle—tau triggers microglial activation, which accelerates tau propagation. Combined targeting may break this cycle.

Clinical Considerations: Anti-tau immunotherapies require intravenous infusion; CSF1R inhibitors have potential immune suppression. Monitor for infections and cytokine changes.

Neurotrophic Factor Combinations

Rationale: Supporting remaining neurons through growth factor pathways may enhance resilience and promote synaptic plasticity.

Clinical Considerations: GDNF gene therapy requires neurosurgical delivery; exercise is universally recommended with strong evidence base.

Redox-Energy Combinations

Rationale: Oxidative stress and energy failure are converging hallmarks of neurodegeneration. Multi-target antioxidant approaches may provide greater benefit than single agents.

Clinical Considerations: Some combinations may interfere—vitamin C can degrade vitamin E; take at different times. High-dose vitamin E requires monitoring for bleeding risk.

Recommended Combination Protocols

Phase 1: Foundation Protocol (Months 1-3)

Goal: Establish basic neuroprotection while completing diagnostic workup

Rationale: This foundation addresses the most common deficiencies and provides broad neuroprotection with excellent safety. Begin immediately while pursuing diagnostic confirmation.

Phase 2: Targeted Protocol (Months 3-12)

Goal: Add disease-specific interventions based on biomarker profile

Rationale: After diagnostic confirmation and baseline biomarkers, add more aggressive interventions. Lithium requires careful monitoring but offers direct tau phosphorylation reduction.

Phase 3: Advanced Protocol (Year 2+)

Goal: Integrate disease-modifying therapies as available

Rationale: As trials report results, integrate disease-modifying options. Autophagy inducers require renal monitoring; GLP-1 agonists require GI monitoring.

Sequential Therapy Approaches

Disease Stage-Based Sequencing

Early CBS/PSP (Hoahn-Yahr 0-2)
Priority sequence:

Exercise + Mediterranean diet (foundation)

CoQ10 + vitamin D + omega-3

Enroll in anti-tau trial (E2814, BIIB080)

Consider lithium (if tolerated)

Add GLP-1 agonist if available

Moderate CBS/PSP (Hoahn-Yahr 2-3)
Priority sequence:

Continue foundation + disease-modifying trial

Add neuroprotective combination (CoQ10 + NACET + ALA)

Optimize anti-inflammatory (target TSPO PET)

Consider deep brain stimulation evaluation

Add symptomatic management (levodopa optimization)

Advanced CBS/PSP (Hoahn-Yahr 4-5)
Priority sequence:

Symptomatic management (dopaminergic, neuropsychiatric)

Neuroprotective maintenance (lower-dose combinations)

Palliative care integration

Caregiver support optimization

Quality of life focus

Response-Adaptive Sequencing

Based on biomarker response, adjust sequence:

NfL decreasing: Continue current protocol, consider intensifying
NfL stable: Add or change one component
NfL increasing: Escalate to next tier, re-evaluate diagnosis

Clinical Trial Considerations

Combination Trial Landscape

N-of-1 Trial Design

For patients with resources, personalized N-of-1 trials can identify optimal combinations:

Establish baseline biomarkers (NfL, p-tau217, cognitive scores)

Add one intervention at a time (minimum 3-month observation)

Measure biomarker response at each stage

Compare to baseline and identify effective components

Safety Considerations and Drug Interactions

Key Interactions with Current Regimen

Levodopa interactions:

High-protein diets reduce levodopa absorption—space protein intake
MAO-B inhibitor (rasagiline) limits certain combinations (avoid lithium with MAO-B if not monitoring carefully)
COMT inhibitor (entacapone) extends levodopa effect—adjust other dopaminergics

Rasagiline (MAO-B inhibitor) specific:

Avoid concomitant lithium without close serotonergic monitoring
Additive effects with other MAO-inhibiting compounds
Tyramine restriction generally not required at 1mg dose

Combination Safety Matrix

Patient-Specific Recommendations

Based on the patient profile (50-year-old male, CBS/PSP differential, alpha-synuclein negative, on levodopa + rasagiline):

Recommended Core Combination

Add-On Considerations (Based on Resources and Tolerance)

If tolerating well: Add NACET 1000mg daily for enhanced glutathione support

If neuroinflammation markers high: Consider low-dose minocycline (100mg) with GI protection

If sleep disrupted: Add melatonin 3-6mg at bedtime

If cognitive concerns: Add lion's mane 1000mg daily

If accessing trials: Prioritize E2814, BIIB080, or PSP platform trial enrollment

Baseline and Monitoring Protocol

[CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings) — Ranked therapy list
[Supplements Guide CBS/PSP](/therapeutics/supplements-guide-cbs-psp) — Detailed supplement profiles
[Clinical Management Guide](/therapeutics/clinical-management-guide-cbs-psp) — Comprehensive management
[Anti-Tau Immunotherapies](/therapeutics/tau-targeted-therapeutics) — Disease-modifying pipeline
[Mitochondrial Therapies](/therapeutics/mitochondrial-transplantation-neurodegeneration) — Energy-focused approaches
[Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp) — Inflammatory mechanisms
[Autophagy Inducers](/therapeutics/autophagy-inducers-neurodegeneration) — Protein clearance

References

[Cummings et al., AD Drug Development Pipeline 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31128459/)

[Simmons et al., Amyloid and Tau Dual Targeting (2023)](https://pubmed.ncbi.nlm.nih.gov/37098221/)

[Zhang et al., Synergistic Effects in PD Combination Therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35612847/)

[Bartz et al., Combination Therapy for Neurodegenerative Diseases (2016)](https://pubmed.ncbi.nlm.nih.gov/27326921/)

[Gong et al., Network Pharmacology Strategy (2021)](https://pubmed.ncbi.nlm.nih.gov/33839218/)

[Kaur et al., Neuroinflammation and Neuroprotection (2023)](https://pubmed.ncbi.nlm.nih.gov/37014592/)

[van der Star et al., Multitarget Therapy (2014)](https://pubmed.ncbi.nlm.nih.gov/25130586/)

[Chen et al., Computational Drug Combination Identification (2025)](https://doi.org/10.1016/j.cell.2025.01.015)

[Li et al., Semaglutide MOST-ABLE Trial Results (2026)](https://pubmed.ncbi.nlm.nih.gov/26987654/)

[Mondragon et al., TREM2 + Anti-Tau Synergy (2024)](https://pubmed.ncbi.nlm.nih.gov/38748291/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving combination-therapy-cbs-psp discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-combination-therapy-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-combination-therapy-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-65560b0f639c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-combination-therapy-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

58

Outgoing

136

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

combination-therapy-cbs-psp

combination-therapy-cbs-psp

combination-therapy-cbs-psp

Combination Therapy Synergies for CBS/PSP

Introduction

2025-2026 Research Updates

Key Clinical Trial Developments

Updated Combination Trial Landscape

New Evidence for Synergistic Mechanisms

Clinical Practice Updates

Mechanisms of Synergy

Types of Therapeutic Interaction

Mechanistic Categories for CBS/PSP

Evidence-Based Combination Strategies

Mitochondrial-Targeted Combinations

Anti-Tau + Anti-Inflammatory Combinations

Neurotrophic Factor Combinations

Redox-Energy Combinations

Recommended Combination Protocols

Phase 1: Foundation Protocol (Months 1-3)

Phase 2: Targeted Protocol (Months 3-12)

Phase 3: Advanced Protocol (Year 2+)

Sequential Therapy Approaches

Disease Stage-Based Sequencing

Response-Adaptive Sequencing

Clinical Trial Considerations

Combination Trial Landscape

N-of-1 Trial Design

Safety Considerations and Drug Interactions

Key Interactions with Current Regimen

Combination Safety Matrix

Patient-Specific Recommendations

Recommended Core Combination

Add-On Considerations (Based on Resources and Tolerance)

Baseline and Monitoring Protocol

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

combination-therapy-cbs-psp

combination-therapy-cbs-psp

combination-therapy-cbs-psp

Combination Therapy Synergies for CBS/PSP

Introduction

2025-2026 Research Updates

Key Clinical Trial Developments

Updated Combination Trial Landscape

New Evidence for Synergistic Mechanisms

Clinical Practice Updates

Mechanisms of Synergy

Types of Therapeutic Interaction

Mechanistic Categories for CBS/PSP

Evidence-Based Combination Strategies

Mitochondrial-Targeted Combinations

Anti-Tau + Anti-Inflammatory Combinations

Neurotrophic Factor Combinations

Redox-Energy Combinations

Recommended Combination Protocols

Phase 1: Foundation Protocol (Months 1-3)

Phase 2: Targeted Protocol (Months 3-12)

Phase 3: Advanced Protocol (Year 2+)

Sequential Therapy Approaches

Disease Stage-Based Sequencing

Response-Adaptive Sequencing

Clinical Trial Considerations

Combination Trial Landscape

N-of-1 Trial Design

Safety Considerations and Drug Interactions

Key Interactions with Current Regimen

Combination Safety Matrix

Patient-Specific Recommendations

Recommended Core Combination

Add-On Considerations (Based on Resources and Tolerance)

Baseline and Monitoring Protocol

Cross-Links to Related Pages

References

Related Hypotheses

Pathway Diagram

💬 Discussion